Doxorubicin Market Growth & Trends
The global doxorubicin market size is expected to reach USD 1.53 billion by 2030, registering a CAGR of 6.6% during the forecast period. The growing number of players in the market to control the shortage of the drug is one of the crucial factors that is expected to drive the market in the coming few years. Some of the doxorubicin manufacturers are Ortho Biotech Products, LP, Ben Venue Laboratories, Inc., and Bristol-Myers Squibb Company. The increasing indication of doxorubicin drug in various applications such as AIDS related Kaposi Sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand for the drug. The technological advancement in the drug formulations to overcome the adverse effects on health and also introduces various types of drug delivery systems such as nanoparticles or liposomal coated are some of the pivotal factors that are impelling the industry growth.
The U.S. government had issued an executive order to overcome the shortage of life saving drugs, chemotherapy agents, and critically needed drugs in the U.S. region, is one of the indicators accounted for the increasing number of players in this sector. Based on the estimates of Surveillance, Epidemiology, and End Results (SEER), the anticipated number of malignancy cases in 2016 are listed below: :
- Leukemia 60,140
- Breast cancer 2,46,660
- Endometrial cancer 60,050
- Gastric cancer 26,370
- Liver cancer 39,230
- Kidney Cancer 62,700
Doxorubicin Market Report Highlights
- In 2023, breast cancer is the largest application of doxorubicin market. The growing demand for the drug in combination therapy with cisplatin is one of the pivotal factors that are expected to impel the doxorubicin market.
- Bladder cancer segment projected to grow at a significant CAGR during the forecast period. Doxorubicin, which has been a standard treatment for advanced bladder cancer, remains a critical component in the management of the disease.
- In 2023, North America held majority of market share of over 37.7% in the global doxorubicin market. The presence of dominating market players such as Johnson & Johnson and Sun Pharmaceuticals Industries Ltd. and rising awareness regarding efficacious drug alternatives are few of the key factors attributed to the regions high market share.
- Asia Pacific is the fastest growing region in this market. The presence of unmet demand for anti-cancer treatment and rapidly growing pharmaceutical industries in countries such as China, Japan, and India are among some factors that are expected to drive the market in the coming few years.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Doxorubicin Market Variables, Trends, & Scope
Chapter 4. Doxorubicin Market: Drug Formulation Estimates & Trend Analysis
Chapter 5. Doxorubicin Market: Application Estimates & Trend Analysis
Chapter 6. Doxorubicin Market: Distribution Channel Estimates & Trend Analysis
Chapter 7. Doxorubicin Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Sun Pharmaceutical Industries Ltd
- Cipla.
- Cadila Pharmaceuticals.
- Novartis AG
- Dr. Reddy’s Laboratories Ltd.
- SRS Life Sciences
- MicroBiopharm Japan Co., Ltd.
- Baxter
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | August 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 989.6 Million |
| Forecasted Market Value ( USD | $ 1530 Million |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
